Sept. 9, 2025 — Neurescue ApS has received CE Mark approval for its Neurescue device, a medical device approved to treat non-shockable cardiac arrest. Granted by TÜV SÜD after an expedited six-month review under Europe’s Medical Device Regulation (MDR), this milestone marks one of the most significant advances in resuscitation since the introduction of CPR in 1960.

Sept. 8, 2025 — Pulse Biosciences, Inc., a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) technology, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation (AF).

Sept. 5, 2025 — Idorsia Ltd has announced a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring multiple medications for difficult-to-control hypertension face increasing challenges with care coordination, evaluation of underlying causes and worsening outcomes.

Sept. 2, 2025 —Corsera Health, Inc. has announced its launch with a mission to extend healthspan through cardiovascular disease prediction and prevention. The company will shape the future of cardiovascular health by empowering individuals to understand and reduce their risk of atherosclerotic cardiovascular disease (ASCVD). With a preventive RNAi medicine expected to enter the clinic by the end of 2025, administered once-annually and priced to enable broad access, Corsera Health aims to prevent cumulative cardiovascular damage and support longer, healthier lives. 

Sept. 2, 2025 — Stereotaxis has announced the successful completion of the world’s first procedures using MAGiC Sweep, a robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New Jersey.